Dr. Kreher brings 13 years of experience in medical affairs and clinical development from leading biotechnology companies, most recently serving as Chief Medical officer at AVROBIO, a gene therapy company.
There, she led all clinical development and clinical operations for multiple global rare disease programs, including programs for Fabry and Gaucher disease, among others.
Nerissa brings deep academic, clinical research and biotechnology industry experience and she has held leadership roles in both clinical development and medical affairs at large, public and private, start-up biotechnology companies.
Prior to AVROBIO, Dr. Kreher was the global head of clinical and medical Affairs at Zafgen, a clinical-stage biopharmaceutical company developing therapies for the treatment of metabolic diseases.
In the role, she led the clinical team responsible for advancing the development of their lead program for Prader-Willi syndrome.
Previously, she was Global Clinical Development Lead for Shire HGT and Executive Medical director of Metabolic Disorders at Alexion Pharmaceuticals.
Kreher began her career as director, Medical Affairs at Serono and medical director at Genzyme.
She received her M.D. from East Carolina University, her B.S. in biology from University of North Carolina at Chapel Hill and an M.S. in clinical research from Indiana University-Purdue University Indianapolis. Dr. Kreher holds an executive MBA from Northeastern University Graduate School of Business Administration.
Tiburio is a clinical stage biopharmaceutical company. Its pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma, and TBR-065 for additional rare endocrine diseases.
The company was launched out of orphan drug accelerator Cydan with financing from leading life sciences investors, New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures, and Alexandria Venture Investments. Tiburio is located in Technology Square in Cambridge, Mass.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer